Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy

106Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There are limited therapeutic options available for patients with autoimmune hepatitis in whom conventional treatment fails. A case series of five patients unresponsive to or unable to take azathioprine, 6-mercaptopurine or corticosteroids who were treated with mycophenolate mofetil (MMF) is reported. While on MMF, alanine aminotransferase normalized or remained normal in all patients. MMF had a steroid-sparing effect and histological remission was demonstrated in one patient after seven months of MMF. One patient experienced an uncomplicated episode of pyelonephritis. In conclusion, MMF can effectively induce and maintain remission in refractory autoimmune hepatitis patients. © 2004 Pulsus Group Inc. All rights reserved.

Cite

CITATION STYLE

APA

Devlin, S. M., Swain, M. G., Urbanski, S. J., & Burak, K. W. (2004). Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Canadian Journal of Gastroenterology, 18(5), 321–326. https://doi.org/10.1155/2004/504591

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free